Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

206 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The effect of GSM and TETRA mobile handset signals on blood pressure, catechol levels and heart rate variability.
Barker AT, Jackson PR, Parry H, Coulton LA, Cook GG, Wood SM. Barker AT, et al. Bioelectromagnetics. 2007 Sep;28(6):433-8. doi: 10.1002/bem.20333. Bioelectromagnetics. 2007. PMID: 17486598
Blood catechols before and after exposure, heart rate variability during exposure, and post exposure 24 h ambulatory blood pressure were also studied. ...
Blood catechols before and after exposure, heart rate variability during exposure, and post exposure 24 h ambulatory blood pressure w …
The angiotensin-converting enzyme gene I/D polymorphism and heart rate variability following acute myocardial infarction.
Steeds RP, Fletcher J, Parry H, Chowdhary S, Channer KS, West J, Townend JN. Steeds RP, et al. Clin Auton Res. 2002 Apr;12(2):66-71. doi: 10.1007/s102860200022. Clin Auton Res. 2002. PMID: 12102452
MAJOR FINDINGS: 149 Caucasian subjects were studied 25 +/- 16 h following MI using time and frequency domain measures of HRV derived from two 5-minute ECG recordings. Recordings were repeated at 182 +/- 65 h following MI, when subjects had been stabilised on ramipri …
MAJOR FINDINGS: 149 Caucasian subjects were studied 25 +/- 16 h following MI using time and frequency domain measures of HRV derived …
State of play of pharmacogenetics and personalized medicine in heart failure.
Parry HM, Doney AS, Palmer CN, Lang CC. Parry HM, et al. Cardiovasc Ther. 2013 Dec;31(6):315-22. doi: 10.1111/1755-5922.12030. Cardiovasc Ther. 2013. PMID: 23480579 Review.
Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure.
Cao TH, Jones DJL, Quinn PA, Chan DCS, Hafid N, Parry HM, Mohan M, Sandhu JK, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, Lang CC, Ng LL. Cao TH, et al. Clin Proteomics. 2018 Nov 2;15:35. doi: 10.1186/s12014-018-9213-1. eCollection 2018. Clin Proteomics. 2018. PMID: 30410428 Free PMC article.
The future of pharmacogenetics in the treatment of heart failure.
Anwar MS, Iskandar MZ, Parry HM, Doney AS, Palmer CN, Lang CC. Anwar MS, et al. Pharmacogenomics. 2015 Nov;16(16):1817-27. doi: 10.2217/pgs.15.120. Epub 2015 Nov 10. Pharmacogenomics. 2015. PMID: 26555119 Review.
Management of Noncardiac Comorbidities in Chronic Heart Failure.
Chong VH, Singh J, Parry H, Saunders J, Chowdhury F, Mancini DM, Lang CC. Chong VH, et al. Cardiovasc Ther. 2015 Oct;33(5):300-15. doi: 10.1111/1755-5922.12141. Cardiovasc Ther. 2015. PMID: 26108139
Genetic Variation in Kruppel like Factor 15 Is Associated with Left Ventricular Hypertrophy in Patients with Type 2 Diabetes: Discovery and Replication Cohorts.
Patel SK, Wai B, Lang CC, Levin D, Palmer CNA, Parry HM, Velkoska E, Harrap SB, Srivastava PM, Burrell LM. Patel SK, et al. EBioMedicine. 2017 Apr;18:171-178. doi: 10.1016/j.ebiom.2017.03.036. Epub 2017 Mar 30. EBioMedicine. 2017. PMID: 28400202 Free PMC article.
206 results
Jump to page
Feedback